Sino Biological/Recombinant Anti-PD-L1 Antibody, Rabbit Monoclonal/1/10084-R015
商品编号：
10084-R015
品牌：
sinobiological
市场价：
¥0.00
美元价：
0.00
联系Q Q：
3392242852
电话号码：
4000-520-616
电子邮箱：
info@ebiomall.com
商品介绍
Recombinant Anti-PD-L1 Antibody, Rabbit Monoclonal General Information
Product name
Recombinant Anti-PD-L1 Antibody, Rabbit Monoclonal
Validated applications
ELISA,IHC-P
Species reactivity
Reacts with: Human
Specificity
Human PD-L1No cross-reactivity in ELISA withHuman B7-1Human B7-2Mouse B7-H1Non-blockingThis B7-H1/PD-L1 antibody can not block the binding of recombinant PD1 (10377-H03H) to its recombinant ligand B7-H1/PD-L1 (10084-H02H).
Immunogen
Recombinant Human PD-L1 / B7-H1 / CD274 protein (Catalog#10084-H08H)
Preparation
This antibody was obtained from a rabbit immunized with purified, recombinant Human PD-L1 / B7-H1 / CD274 (rh PD-L1 / B7-H1 / CD274; Catalog#10084-H08H; NP_054862.1; Met 1-Thr 239).
Source
Monoclonal Rabbit IgG Clone #015
Purification
Protein A
Formulation
0.2 μm filtered solution in PBS
Conjugate
Unconjugated
Form
Liquid
Shipping
This antibody is shipped as liquid solution at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Storage
This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Preservative-Free. Avoid repeated freeze-thaw cycles.
Recombinant Anti-PD-L1 Antibody, Rabbit Monoclonal Validated Applications
| Application | Dilution |
|---|---|
| ELISA | 1:5000-1:10000 |
| IHC-P | 1:100-1:500 |
Please Note: Optimal concentrations/dilutions should be determined by the end user.
Recombinant Anti-PD-L1 Antibody, Rabbit Monoclonal Images
Immunochemical staining of human B7H1 in human placenta with rabbit monoclonal antibody (1:200, formalin-fixed paraffin embedded sections). Positive staining was localized to trophoblast.
Recombinant Anti-PD-L1 Antibody, Rabbit Monoclonal: Synonyms
Anti-B7-H Antibody; Anti-B7-H1 Antibody; Anti-B7H1 Antibody; Anti-PD-L1 Antibody; Anti-PDCD1L1 Antibody; Anti-PDCD1LG1 Antibody; Anti-PDL1 Antibody
PD-L1 Background Information
Programmed death-1 ligand-1 (PD-L1, CD274, B7-H1) has been identified as the ligand for the immunoinhibitory receptor programmed death-1(PD1/PDCD1) and has been demonstrated to play a role in the regulation of immune responses and peripheral tolerance. PD-L1/B7-H1 is a member of the growing B7 family of immune molecules and this protein contains one V-like and one C-like Ig domain within the extracellular domain, and together with PD-L2, are two ligands for PD1 which belongs to the CD28/CTLA4 family expressed on activated lymphoid cells. By binding to PD1 on activated T-cells and B-cells, PD-L1 may inhibit ongoing T-cell responses by inducing apoptosis and arresting cell-cycle progression. Accordingly, it leads to growth of immunogenic tumor growth by increasing apoptosis of antigen specific T cells and may contribute to immune evasion by cancers. PD-L1 thus is regarded as promising therapeutic target for human autoimmune disease and malignant cancers.
- Cancer Immunotherapy
- Co-inhibitory Immune Checkpoint Targets
- Immune Checkpoint
- Immune Checkpoint Blockade: Blocking Antibodi
- Immune Checkpoint Blockade: PD-L1 / B7-H1 / C
- Immune Checkpoint Detection: Antibodies
- Immune Checkpoint Detection: ELISA Antibodies
- Immune Checkpoint Detection: FCM Antibodies
- Immune Checkpoint Detection: ICC Antibodies
- Immune Checkpoint Detection: IHC Antibodies
- Immune Checkpoint Detection: WB Antibodies
- Immune Checkpoint Proteins
- Immune Checkpoint Targets
- Immunotherapy
- PD-L1 / B7-H1 / CD274 Immune Checkpoint Prote
- Targeted Therapy
Full Name
CD274 molecule
Research Areas
- Cancer Drug Targets
References
- Iwai Y, et al. (2002) Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A. 99(19): 12293-7.
- Ghebeh H, et al. (2006) The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. Neoplasia. 8(3): 190-8.
- Salih HR, et al. (2006) The role of leukemia-derived B7-H1 (PD-L1) in tumor-T-cell interactions in humans. Exp Hematol. 34(7): 888-94.
- Wilcox RA, et al. (2009) B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders. Blood. 114(10): 2149-58.
- Ruggiero A, et al. (2009) Crystal structure of PD-L1, a ribosome inactivating protein from Phytolacca dioica L. leaves with the property to induce DNA cleavage. Biopolymers. 91(12): 1135-42.
- PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignanciesAuthorBJ Chen, B Chapuy, J Ouyang, HH Sun…Year2013JournalClinical Cancer researchApplicationbindingPubMed ID: 23674495FoldedExpand
- PD-L1 Expression Is Increased in a Subset of Basal Type Breast Cancer CellsAuthorSoliman, H;Khalil, F;Antonia, S;Year2014JournalPLoS ONEApplicationIHCPubMed ID: 24551119FoldedExpand
- Magnitude of PD-1, PD-L1 and T Lymphocyte Expression on Tissue from Castration-Resistant Prostate Adenocarcinoma: An Exploratory AnalysisAuthorMassari, F;Ciccarese, C;Caliò, A;Munari, E;Cima, L;Porcaro, AB;Novella, G;Artibani, W;Sava, T;Eccher, A;Ghimenton, C;Bertoldo, F;Scarpa, A;Sperandio, N;Porta, C;Bronte, V;Chilosi, M;Bogina, G;Zamboni, G;Tortora, G;Samaratunga, H;Martignoni, G;Brunelli, M;Year2015JournalTarget OncolApplicationIHCFoldedExpand
- PD-L1 Antibodies to Its Cytoplasmic Domain Most Clearly Delineate Cell Membranes in Immunohistochemical Staining of Tumor CellsAuthorMahoney, KM;Sun, H;Liao, X;Hua, P;Callea, M;Greenfield, EA;Hodi, FS;Sharpe, AH;Signoretti, S;Rodig, SJ;Freeman, GJ;Year2015JournalCancer Immunol ResApplicationIHCPubMed ID: 26546452FoldedExpand
- Developing a LANCE TR-FRET Assay for Screening PD-1 and PD-L1 Binding InhibitorsAuthorHinterneder, J;Hopkinton, MA;Year2017JournalProductApplicationcontrol assayFoldedExpand
- Gene signature driving invasive mucinous adenocarcinoma of the lungAuthorGuo, M;Tomoshige, K;Meister, M;Muley, T;Fukazawa, T;Tsuchiya, T;Karns, R;Warth, A;Fink-Baldauf, IM;Nagayasu, T;Naomoto, Y;Xu, Y;Mall, MA;Maeda, Y;Year2017JournalEMBO Mol MedApplicationWBPubMed ID: 28255028FoldedExpand
If you couldn"t find the specific citation, you can:
- Find All Citations
- Submit a CitationGet a Publication Reward
- Leave Us a Message
Recombinant Antibody Production Service
High-throughput Recombinant Antibody Production
Large-scale Antibody Production
Antibody Development Service
Rabbit MAb Production Service
Mouse MAb Production Service
Rabbit PAb Production Service
Phospho-Specific Antibody
Anti-Idiotype Antibody
Fast Antibody Development Service
Mouse MAb
Rabbit PAb
More Antibody Production Service
Hybridoma Antibody Production
Chimeric Antibody
Antibody Fragment
Bispecific Antibody
We also have Immunoassay Service. Click to see more.
品牌介绍
北京义翘神州科技股份有限公司（Sino Biological Inc.）是一家从事生物试剂研发、生产、销售并提供技术服务的生物科技公司，主要业务包括重组蛋白、抗体、基因和培养基等产品，以及重组蛋白、抗体的开发和生物分析检测等服务。义翘神州为全球的药品研发企业和生命科学研究机构提供高质量的生物试剂产品和高水平的技术服务。公司目前生产和销售的现货产品种类超过 4.6 万种，其中重组蛋白约 6,000 种，包括超过 3,800 种人源细胞表达重组蛋白产品，能够全面满足客户对于最接近人体天然蛋白结构和性质的重组蛋白需求；公司还能提供约 12,000 种抗体，其中单克隆抗体数量约 4,600 种，能够覆盖生命科学研究的多个领域，为分子生物学、细胞生物学、免疫学、发育生物学、干细胞研究等基础科研方向和创新药物研发提供「一站式」生物试剂产品和技术服务。义翘神州的客户涵盖大学、科研院所、医药研发企业等国内外各类生物研发单位。目前公司已经在美国、欧洲建立了子公司，已成为生物试剂行业国内领先的科技公司之一。
联络我们
